Diabetes Market Research Reports & Industry Analysis
Glucose monitors have a major consumer-marketing component. While physicians may prescribe a monitor, the patient ultimately has the choice of which monitor s/he uses. Insulin provides very little consumer choice. The treatment regimen prescribed by the physician must be followed and there are very few market options. With Eli Lilly and Novo Nordisk being the two largest producers of insulin, it is highly likely that an insulin user will wind up using one of their products. As time goes by, the options of oral insulin and more intranasal insulin products may offer insulin dependent diabetics more variety in terms of products and delivery methods.
Hypoglycemic agents abound and vary in their composition and mode of action. For the most part, advanced cases of Type 2 diabetes require more than one of these drugs in order for the patient to maintain glycemic control. Because of the wide variety of these products, there is some room for pharmaceutical companies to influence diabetics toward using their products. In the end, the physician may have the last word, but that does not mean that the patient will stay with a physician who does not acquiesce to his/her wishes.
Diabetes Industry Research & Market Reports
-
Glucose Monitoring Devices
... at a CAGR of 4.6% over the analysis period 2024-2030. Self-Monitoring Devices, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$11.3 Billion by the end of ... Read More
-
Human Insulin
... CAGR of 6.8% over the analysis period 2024-2030. HI Drugs, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$70.6 Billion by the end of the analysis ... Read More
-
Metabolic Disorder Therapeutics
... at a CAGR of 6.9% over the analysis period 2024-2030. Diabetes, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$91.9 Billion by the end of the ... Read More
-
Smart Insulin Pens and Pumps
... Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Pumps, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$7.9 Billion by ... Read More
-
Desmopressin
... 5.6% over the analysis period 2024-2030. Injectable Solution, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$866.1 Million by the end of the analysis period. Growth ... Read More
-
Insulin Patch Pumps
... at a CAGR of 9.8% over the analysis period 2024-2030. Basal & Bolus, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$1.4 Billion by the end ... Read More
-
Blood Glucose Meters
... at a CAGR of 6.6% over the analysis period 2024-2030. Self-Monitoring, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$36.8 Billion by the end of the ... Read More
-
Insulin Pens
... CAGR of 7.2% over the analysis period 2024-2030. Disposable, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$11.6 Billion by the end of the analysis period. ... Read More
-
Diabetic Retinopathy Treatment
... at a CAGR of 5.0% over the analysis period 2024-2030. Non-Proliferative Diabetic Retinopathy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$7.5 Billion by the end ... Read More
-
Diabetic Macular Edema Treatment
... 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Anti-VEGF, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$2.7 Billion by the end ... Read More
-
Diabetic Nephropathy Treatment
... at a CAGR of 4.8% over the analysis period 2024-2030. Angiotensin Receptor Blockers (ARBs), one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$1.8 Billion by the ... Read More
-
Diabetic Foot Ulcers and Pressure Ulcers
... reach US$6.0 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Diabetic Foot Ulcers, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and ... Read More
-
Insulin Pen Needles
... at a CAGR of 6.7% over the analysis period 2024-2030. Standard Insulin Pen Needles, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$2.7 Billion by the ... Read More
-
Nocturia Drugs
... CAGR of 6.1% over the analysis period 2024-2030. Low Nocturnal Bladder Capacity, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$3.0 Billion by the end of ... Read More
-
Diabetic Food
... CAGR of 4.8% over the analysis period 2024-2030. Dietary Beverages, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$6.2 Billion by the end of the analysis ... Read More
-
Canada Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive Landscape – Q2 2025 Update
... a CAGR of 12.9%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 10.0% during 2025-2029. By the end of 2029, the diabetes market is projected to ... Read More
-
Argentina Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive Landscape – Q2 2025 Update
... a CAGR of 8.1%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 6.3% during 2025-2029. By the end of 2029, the diabetes market is projected to ... Read More
-
Thailand Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive Landscape – Q2 2025 Update
... a CAGR of 8.2%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 6.3% during 2025-2029. By the end of 2029, the diabetes market is projected to ... Read More
-
Malaysia Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive Landscape – Q2 2025 Update
... a CAGR of 7.9%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 6.2% during 2025-2029. By the end of 2029, the diabetes market is projected to ... Read More
-
Switzerland Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive Landscape – Q2 2025 Update
... a CAGR of 11.8%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 9.2% during 2025-2029. By the end of 2029, the diabetes market is projected to ... Read More
-
Global Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive Landscape – Q2 2025 Update
... CAGR of 9.7%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.6% during 2025-2029. By the end of 2029, the diabetes market is projected to expand ... Read More
-
Taiwan Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive Landscape – Q2 2025 Update
... a CAGR of 10.1%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.9% during 2025-2029. By the end of 2029, the diabetes market is projected to ... Read More
-
Singapore Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive Landscape – Q2 2025 Update
... a CAGR of 9.4%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.2% during 2025-2029. By the end of 2029, the diabetes market is projected to ... Read More
-
Turkey Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive Landscape – Q2 2025 Update
... a CAGR of 8.5%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 6.7% during 2025-2029. By the end of 2029, the diabetes market is projected to ... Read More
-
Bangladesh Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive Landscape – Q2 2025 Update
... a CAGR of 7.2%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 5.7% during 2025-2029. By the end of 2029, the diabetes market is projected to ... Read More
Research Assistance
